Massachusetts-based cannabis company Curaleaf CURLF has settled another class-action lawsuit related to its Select brand CBD drops containing THC.
What Happened?
- The settlement, the second in the case, stems from when the company mixed up its two lines of products – one with CBD and the other with THC, causing confusing states for some of its consumers who were not expecting to get stoned from their CBD drops.
Oregon state regulators had to recall the brand’s 1,000mg unflavored Select CBD drops, labeled as “Broad Spectrum,” but that contained THC. And then the brand’s 1,000-mg bottles of unflavored, Select THC Tincture had to be recalled for not containing THC. - The company attributed the incident to unintentional human error.
- This latest settlement, totaling $100,000, will establish a fund to compensate the affected consumers, allowing them to claim $150-$200 each if they purchased mislabeled Select CBD drops after June 19, 2021.
- The settlement was reached after negotiations with plaintiff Ronald Williamson, who filed the motion in Oregon federal court seeking approval.
- Williamson's attorneys plan to seek no more than 25% of the fund to cover court costs and legal fees.
- This is not the first time for Curaleaf. The company agreed to another settlement for approximately $50,000.
Related News
-
Curaleaf Q1 Revenue Grows 14%, Optimizing U.S. Assets & Heading To Europe Says Boss Boris Jordan
-
Curaleaf Stock Trading Lower On FY22 Net Revenue Growth Of 12%
-
EXCLUSIVE: Streamlining The Cannabis Industry - Collaboration, Data Sharing In The Supply Chain
Photo: Edward Lich via Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.